Recon: MHRA staff fret over planned budget cuts; FDA rejects Sesen Bio's bladder cancer drug
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy